Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Int J Gynecol Cancer. 2010 Oct;20(7):1290–1298. doi: 10.1111/IGC.0b013e3181ee1c01

Table 1.

Novel targets and agents in epithelial ovarian cancer

Targets Agents under study in ovarian cancer
Angiogenesis bevacizumab, cediranib, sorafenib,
sunitinib, aflibercept, pazopanib, BIBF-
1120
Epidermal growth factor receptor
(EGFR)		 erlotinib
Fibroblast growth factor receptor
(FGFR)		 BIBF-1120
Mammalian target of rapamycin (mTOR) Temsirolimus, everolimus, deforolimus,
sirolimus
Phosphatase and tensin homolog
(PTEN)/ AKT protein kinase family		 perifosine, PBI-05204, GSK 2141795
Phosphoinositide 3-kinase (PI3K)/
Mammalian target of rapamycin (mTOR)		 XL147, PX-866, PI-103, GDC-0941,
BKM120
Platelet-derived growth factor receptor
(PDGFR)		 Cediranib, pzapanib, BIBF-1120
Poly (ADP-ribose) polymerase (PARP) ABT-888 (veliparib), AZD 2281
(olaparib), AG014699, BSI-201
(iniparib), INO-1001, MK 4827, GPI
21016